This adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.
At this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.
And, pointed out Dr. Lucas Wong, associate professor of internal medicine at Texas A&M Health Science Center College of Medicine and co-director of the Gastrointestinal Cancer Program at Scott & White in Temple, Texas, while the new research is "interesting and thought-provoking, what's proven in humans is totally another level."
The U.S. National Library of Medicine has more on metformin.
SOURCES: Lucas Wong, M.D., associate professor of internal medicine, Texas A&M Health Science Center College of Medicine and co-director, Gastrointestinal Cancer Program, Scott & White, Temple, Texas; Sept. 1, 2010 teleconference with Scott Lippman, M.D., editor-in-chief, Cancer Prevention Research and professor and chair, department of thoracic head and neck medical oncology, University of Texas M.D. Anderson Cancer Center; Michael Pollack, M.D., professor of medicine and oncology, McGill University, Montreal; Phillip Dennis, M.D., Ph.D., senior investigator, U.S. National Cancer Institute; Lewis Cantley, Ph.D., director, Cancer Center, Beth Israel Deaconess Medical Center, Boston; September 2010, Cancer Prevention Research
All rights reserved